| Bioactivity | RPH-2823, a basic triamterene derivative, induces a dose-dependent decrease in short-circuit current (SCC) and increase in transepithelial electrical resistance[1]. | ||||||||||||
| Invitro | RPH-2823 influences transepithelial Na+ transport by interacting with the Na+ channel or a regulator site of it within the apical membrane[1]. | ||||||||||||
| In Vivo | RPH 2823 (2.5 mumol/kg) can avoid the kaliuresis of 25 mumol/kg furosemide in male Wistar rats. RPH 2823 (1 mg/kg and 5 mg/kg, i.v.) has a terminal elimination half-life of 3 h. About 47% of the given dose are excreted unchanged with urine[2]. | ||||||||||||
| Name | RPH-2823 | ||||||||||||
| CAS | 96558-24-6 | ||||||||||||
| Formula | C17H22N8O2 | ||||||||||||
| Molar Mass | 370.41 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Kipnowski J, et al. Effects of standard diuretics and RPH 2823 on transepithelial Na+ transport in isolated frog skin. Klin Wochenschr. 1986;64(16):750-759. [2]. Priewer H, et al. Pharmacodynamics and pharmacokinetics of the basic triamterene analogue dimethylaminohydroxypropoxytriamterene. Arzneimittelforschung. 1985;35(11):1688-1691. |